100 related articles for article (PubMed ID: 25534391)
1. Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation.
Eapen M; Logan BR; Horowitz MM; Zhong X; Perales MA; Lee SJ; Rocha V; Soiffer RJ; Champlin RE
J Clin Oncol; 2015 Feb; 33(4):364-9. PubMed ID: 25534391
[TBL] [Abstract][Full Text] [Related]
2. Impact of stem cell selection between bone marrow and peripheral blood stem cells for unrelated hematopoietic stem cell transplantation for hematologic malignancies: on behalf of the Donor/Source Working Group of the Japanese Society for Transplantation and Cellular Therapy.
Hayashi H; Iwasaki M; Nakasone H; Tanoshima R; Shimabukuro M; Takeda W; Nishida T; Kako S; Fujiwara SI; Katayama Y; Sawa M; Serizawa K; Matsuoka KI; Uchida N; Ikeda T; Ohigashi H; Fukushima K; Hino M; Kanda Y; Fukuda T; Atsuta Y; Kanda J
Cytotherapy; 2024 Feb; 26(2):178-184. PubMed ID: 38108686
[TBL] [Abstract][Full Text] [Related]
3. Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation.
Ueda Oshima M; Xie H; Zamora D; Flowers ME; Hill GR; Mielcarek MB; Sandmaier BM; Gooley TA; Boeckh MJ
Blood Adv; 2023 Apr; 7(8):1394-1403. PubMed ID: 36595478
[TBL] [Abstract][Full Text] [Related]
4. Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia.
Eapen M; Le Rademacher J; Antin JH; Champlin RE; Carreras J; Fay J; Passweg JR; Tolar J; Horowitz MM; Marsh JC; Deeg HJ
Blood; 2011 Sep; 118(9):2618-21. PubMed ID: 21677312
[TBL] [Abstract][Full Text] [Related]
5. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.
MacMillan ML; Robin M; Harris AC; DeFor TE; Martin PJ; Alousi A; Ho VT; Bolaños-Meade J; Ferrara JL; Jones R; Arora M; Blazar BR; Holtan SG; Jacobsohn D; Pasquini M; Socie G; Antin JH; Levine JE; Weisdorf DJ
Biol Blood Marrow Transplant; 2015 Apr; 21(4):761-7. PubMed ID: 25585275
[TBL] [Abstract][Full Text] [Related]
6. ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation.
Logan AC; Wang Z; Alimoghaddam K; Wong RM; Lai T; Negrin RS; Grumet C; Logan BR; Zhang MJ; Spellman SR; Lee SJ; Miklos DB;
Biol Blood Marrow Transplant; 2015 Apr; 21(4):746-54. PubMed ID: 25572032
[TBL] [Abstract][Full Text] [Related]
7. HLA mismatching in transplantation.
Petersdorf EW
Blood; 2015 Feb; 125(7):1058-9. PubMed ID: 25678436
[No Abstract] [Full Text] [Related]
8. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation.
Holtan SG; DeFor TE; Lazaryan A; Bejanyan N; Arora M; Brunstein CG; Blazar BR; MacMillan ML; Weisdorf DJ
Blood; 2015 Feb; 125(8):1333-8. PubMed ID: 25593335
[TBL] [Abstract][Full Text] [Related]
9. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.
Ciurea SO; Zhang MJ; Bacigalupo AA; Bashey A; Appelbaum FR; Aljitawi OS; Armand P; Antin JH; Chen J; Devine SM; Fowler DH; Luznik L; Nakamura R; O'Donnell PV; Perales MA; Pingali SR; Porter DL; Riches MR; Ringdén OT; Rocha V; Vij R; Weisdorf DJ; Champlin RE; Horowitz MM; Fuchs EJ; Eapen M
Blood; 2015 Aug; 126(8):1033-40. PubMed ID: 26130705
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.
Röllig C; Bornhäuser M; Kramer M; Thiede C; Ho AD; Krämer A; Schäfer-Eckart K; Wandt H; Hänel M; Einsele H; Aulitzky WE; Schmitz N; Berdel WE; Stelljes M; Müller-Tidow C; Krug U; Platzbecker U; Wermke M; Baldus CD; Krause SW; Stölzel F; von Bonin M; Schaich M; Serve H; Schetelig J; Ehninger G
J Clin Oncol; 2015 Feb; 33(5):403-10. PubMed ID: 25547501
[TBL] [Abstract][Full Text] [Related]
11. Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies.
Olsson RF; Logan BR; Chaudhury S; Zhu X; Akpek G; Bolwell BJ; Bredeson CN; Dvorak CC; Gupta V; Ho VT; Lazarus HM; Marks DI; Ringdén OT; Pasquini MC; Schriber JR; Cooke KR
Leukemia; 2015 Aug; 29(8):1754-62. PubMed ID: 25772027
[TBL] [Abstract][Full Text] [Related]
12. Effect of cord blood processing on transplantation outcomes after single myeloablative umbilical cord blood transplantation.
Ballen KK; Logan BR; Laughlin MJ; He W; Ambruso DR; Armitage SE; Beddard RL; Bhatla D; Hwang WY; Kiss JE; Koegler G; Kurtzberg J; Nagler A; Oh D; Petz LD; Price TH; Quinones RR; Ratanatharathorn V; Rizzo JD; Sazama K; Scaradavou A; Schuster MW; Sender LS; Shpall EJ; Spellman SR; Sutton M; Weitekamp LA; Wingard JR; Eapen M
Biol Blood Marrow Transplant; 2015 Apr; 21(4):688-95. PubMed ID: 25543094
[TBL] [Abstract][Full Text] [Related]
13. Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802.
Holtan SG; Verneris MR; Schultz KR; Newell LF; Meyers G; He F; DeFor TE; Vercellotti GM; Slungaard A; MacMillan ML; Cooley SA; Blazar BR; Panoskaltsis-Mortari A; Weisdorf DJ
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1029-36. PubMed ID: 25759146
[TBL] [Abstract][Full Text] [Related]
14. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.
Paczesny S; Hakim FT; Pidala J; Cooke KR; Lathrop J; Griffith LM; Hansen J; Jagasia M; Miklos D; Pavletic S; Parkman R; Russek-Cohen E; Flowers ME; Lee S; Martin P; Vogelsang G; Walton M; Schultz KR
Biol Blood Marrow Transplant; 2015 May; 21(5):780-92. PubMed ID: 25644957
[TBL] [Abstract][Full Text] [Related]
15. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group.
Schroeder T; Rachlis E; Bug G; Stelljes M; Klein S; Steckel NK; Wolf D; Ringhoffer M; Czibere A; Nachtkamp K; Dienst A; Kondakci M; Stadler M; Platzbecker U; Uharek L; Luft T; Fenk R; Germing U; Bornhäuser M; Kröger N; Beelen DW; Haas R; Kobbe G
Biol Blood Marrow Transplant; 2015 Apr; 21(4):653-60. PubMed ID: 25540937
[TBL] [Abstract][Full Text] [Related]
16. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
Chen YB; Lane AA; Logan B; Zhu X; Akpek G; Aljurf M; Artz A; Bredeson CN; Cooke KR; Ho VT; Lazarus HM; Olsson R; Saber W; McCarthy P; Pasquini MC
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1046-1053. PubMed ID: 25687795
[TBL] [Abstract][Full Text] [Related]
17. Association between donor leukocyte telomere length and survival after unrelated allogeneic hematopoietic cell transplantation for severe aplastic anemia.
Gadalla SM; Wang T; Haagenson M; Spellman SR; Lee SJ; Williams KM; Wong JY; De Vivo I; Savage SA
JAMA; 2015 Feb; 313(6):594-602. PubMed ID: 25668263
[TBL] [Abstract][Full Text] [Related]
18. Estimating demand and unmet need for allogeneic hematopoietic cell transplantation in the United States using geographic information systems.
Besse KL; Preussler JM; Murphy EA; Denzen EM; Lill MC; Chell JW; Senneka MK; Majhail NS; Williams EP
J Oncol Pract; 2015 Mar; 11(2):e120-30. PubMed ID: 25784576
[TBL] [Abstract][Full Text] [Related]
19. Editorial: To the memory of John P. Klein.
Keiding N; Andersen PK; Zhang MJ
Lifetime Data Anal; 2015 Apr; 21(2):157-9. PubMed ID: 25656601
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
